Update shared on 15 Aug 2025
Fair value Decreased 21%Veru’s future P/E has increased and its net profit margin has declined, indicating deteriorating profitability expectations, but analysts maintain their fair value estimate unchanged at $25.00.
What's in the News
- Veru announced a novel modified release oral formulation for enobosarm in chronic weight loss, achieving target pharmacokinetics and leveraging proprietary delivery technology with positive Phase 2b efficacy and safety data.
- The Phase 2b QUALITY and Maintenance Extension studies showed enobosarm significantly reduces weight regain, prevents fat regain, and preserves lean mass after semaglutide discontinuation, supporting a higher quality weight reduction.
- Veru has been granted an FDA meeting to discuss Phase 3 enobosarm program plans, following positive regulatory feedback on trial design and patent protection targeting expiry in 2045.
- Veru shareholders approved a reverse stock split of common stock, to be executed at an eventual 1-for-10 ratio.
- The company expects the new modified release enobosarm formulation to enter Phase 1 bioavailability studies in the first half of 2025, with plans to use it in Phase 3 and eventual commercialization.
Valuation Changes
Summary of Valuation Changes for Veru
- The Consensus Analyst Price Target remained effectively unchanged, at $25.00.
- The Future P/E for Veru has risen from 58.15x to 61.79x.
- The Net Profit Margin for Veru has fallen from 23.22% to 21.85%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.